Work

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

Year: 2026

Type: article

Abstract: Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.

Source: PLoS Medicine

DOI: 10.1371/journal.pmed.1004930

Authors: Giulia Notini, Giampaolo Bianchini, José Manuel Pérez-García, Javier Cortés

Institutions: Vita-Salute San Raffaele University, MedSIR (Spain), IRCCS Ospedale San Raffaele, Hospital Universitario de Torrejón, Universidad Europea de Madrid

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $6,460